RxDoctor Payments Data

Glenn Davis, MD

Internal Medicine · Spring, TXNPI 1003806431

Payments from drug & device makers

$135,813in general payments, 2019–2025

Across 383 payments — averaging $354.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$124K
  • Sanofi Pasteur Inc.$6K
  • Lilly USA, LLC$787
  • Novo Nordisk$749
  • Amgen$639
  • AstraZeneca$638
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$6,98898%
  • Education$270%
  • Entertainment$891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$135,813 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$301,263
Medicare patients
502
Services billed
4,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$54,272
MounjaroTirzepatide41$40,402
XareltoRivaroxaban15$19,727
FarxigaDapagliflozin Propanediol20$15,858
JardianceEmpagliflozin14$11,782
EdarbiAzilsartan Medoxomil14$8,511
Repatha SureclickEvolocumab13$6,976
Rosuvastatin Calcium393$5,436
SynthroidLevothyroxine Sodium85$4,101
Doxycycline Hyclate15$3,315
PremarinEstrogens, Conjugated12$2,600
Valsartan87$2,599
Levothyroxine Sodium269$2,563
Ezetimibe72$2,214
Albuterol Sulfate HfaAlbuterol Sulfate67$1,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$749$54,27238 claims
Lilly USA, LLCMounjaro$787$40,40241 claims
Johnson & JohnsonXarelto$181$19,72715 claims
AstraZenecaFarxiga$638$15,85820 claims
Boehringer IngelheimJardiance$284$11,78214 claims
Arbor Pharmaceuticals, Inc.Edarbi$12$8,51114 claims
AbbVieSynthroid$493$4,10185 claims
PfizerPremarin$123,660$2,60012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Spring

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →